Bronchial reactivity to histamine before and after sodium cromoglycate in bronchial asthma

Bann Kang, C. K. Lee, Betty Miller Kolotkin, Robert G. Townley

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Out of 19 patients with extrinsic bronchial asthma challenged with 123 μg histamine acid phosphate by intravenous infusion only 13 responded with a fall in FEV1 of over 10% (mean 16%). Seventeen of these patients were given histamine 2 mg/ml by aerosol, and all responded with a mean decrease in FEVi of 37.8%. When challenged with allergen extract by aerosol the mean decrease in FEVi was 37.5%. After 40 mg sodium cromoglycate 15 of the 17 patients showed significant protection against allergen challenge with a mean decrease in FEV1 of only 23.6%. Inhalation of 40 mg sodium cromoglycate, however, failed to protect against histamine given by either the intravenous or aerosol route. Histamine given intravenously to asthmatic patients produces less of a bronchial response than when given by aerosol, even though the intravenous route produces many more systemic symptoms, such as flushing and throbbing headache. The protection of sodium cromoglycate against an allergen inhalation challenge is not due to histamine antagonism.

Original languageEnglish
Pages (from-to)867-870
Number of pages4
JournalBritish Medical Journal
Volume1
Issue number6014
DOIs
StatePublished - Apr 10 1976

Fingerprint

Cromolyn Sodium
Aerosols
Histamine
Asthma
Allergens
Inhalation
Intravenous Infusions
Headache

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Bronchial reactivity to histamine before and after sodium cromoglycate in bronchial asthma. / Kang, Bann; Lee, C. K.; Kolotkin, Betty Miller; Townley, Robert G.

In: British Medical Journal, Vol. 1, No. 6014, 10.04.1976, p. 867-870.

Research output: Contribution to journalArticle

Kang, Bann ; Lee, C. K. ; Kolotkin, Betty Miller ; Townley, Robert G. / Bronchial reactivity to histamine before and after sodium cromoglycate in bronchial asthma. In: British Medical Journal. 1976 ; Vol. 1, No. 6014. pp. 867-870.
@article{434614363d3045328047f4d5a4113f51,
title = "Bronchial reactivity to histamine before and after sodium cromoglycate in bronchial asthma",
abstract = "Out of 19 patients with extrinsic bronchial asthma challenged with 123 μg histamine acid phosphate by intravenous infusion only 13 responded with a fall in FEV1 of over 10{\%} (mean 16{\%}). Seventeen of these patients were given histamine 2 mg/ml by aerosol, and all responded with a mean decrease in FEVi of 37.8{\%}. When challenged with allergen extract by aerosol the mean decrease in FEVi was 37.5{\%}. After 40 mg sodium cromoglycate 15 of the 17 patients showed significant protection against allergen challenge with a mean decrease in FEV1 of only 23.6{\%}. Inhalation of 40 mg sodium cromoglycate, however, failed to protect against histamine given by either the intravenous or aerosol route. Histamine given intravenously to asthmatic patients produces less of a bronchial response than when given by aerosol, even though the intravenous route produces many more systemic symptoms, such as flushing and throbbing headache. The protection of sodium cromoglycate against an allergen inhalation challenge is not due to histamine antagonism.",
author = "Bann Kang and Lee, {C. K.} and Kolotkin, {Betty Miller} and Townley, {Robert G.}",
year = "1976",
month = "4",
day = "10",
doi = "10.1136/bmj.1.6014.867",
language = "English",
volume = "1",
pages = "867--870",
journal = "The BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "6014",

}

TY - JOUR

T1 - Bronchial reactivity to histamine before and after sodium cromoglycate in bronchial asthma

AU - Kang, Bann

AU - Lee, C. K.

AU - Kolotkin, Betty Miller

AU - Townley, Robert G.

PY - 1976/4/10

Y1 - 1976/4/10

N2 - Out of 19 patients with extrinsic bronchial asthma challenged with 123 μg histamine acid phosphate by intravenous infusion only 13 responded with a fall in FEV1 of over 10% (mean 16%). Seventeen of these patients were given histamine 2 mg/ml by aerosol, and all responded with a mean decrease in FEVi of 37.8%. When challenged with allergen extract by aerosol the mean decrease in FEVi was 37.5%. After 40 mg sodium cromoglycate 15 of the 17 patients showed significant protection against allergen challenge with a mean decrease in FEV1 of only 23.6%. Inhalation of 40 mg sodium cromoglycate, however, failed to protect against histamine given by either the intravenous or aerosol route. Histamine given intravenously to asthmatic patients produces less of a bronchial response than when given by aerosol, even though the intravenous route produces many more systemic symptoms, such as flushing and throbbing headache. The protection of sodium cromoglycate against an allergen inhalation challenge is not due to histamine antagonism.

AB - Out of 19 patients with extrinsic bronchial asthma challenged with 123 μg histamine acid phosphate by intravenous infusion only 13 responded with a fall in FEV1 of over 10% (mean 16%). Seventeen of these patients were given histamine 2 mg/ml by aerosol, and all responded with a mean decrease in FEVi of 37.8%. When challenged with allergen extract by aerosol the mean decrease in FEVi was 37.5%. After 40 mg sodium cromoglycate 15 of the 17 patients showed significant protection against allergen challenge with a mean decrease in FEV1 of only 23.6%. Inhalation of 40 mg sodium cromoglycate, however, failed to protect against histamine given by either the intravenous or aerosol route. Histamine given intravenously to asthmatic patients produces less of a bronchial response than when given by aerosol, even though the intravenous route produces many more systemic symptoms, such as flushing and throbbing headache. The protection of sodium cromoglycate against an allergen inhalation challenge is not due to histamine antagonism.

UR - http://www.scopus.com/inward/record.url?scp=0017255099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017255099&partnerID=8YFLogxK

U2 - 10.1136/bmj.1.6014.867

DO - 10.1136/bmj.1.6014.867

M3 - Article

VL - 1

SP - 867

EP - 870

JO - The BMJ

JF - The BMJ

SN - 0959-8146

IS - 6014

ER -